Potential Therapeutic Roles for IBAT Inhibitors in Cholestatic and Metabolic Liver Diseases

Written on Monday 12th October 2020

Potential Therapeutic Roles for IBAT Inhibitors in Cholestatic and Metabolic Liver Diseases

Independent symposium chaired by Dr Saul Karpen

With Dr Paul Dawson, Dr Kathleen Loomes, and Dr Arun Sanyal

Sunday November 15TH 2020 | 19:00 – 21:00 ET

Presentations

  1. Welcome & pre-activity information
    Dr Saul Karpen
  2. Ileal bile acid transport (IBAT) inhibitors: mechanism of action and physiological effects
    Dr Paul Dawson
  3. Potential therapeutic roles for IBAT inhibitors in cholestatic liver disease: a case of Alagille syndrome
    Dr Kathleen Loomes
  4. Potential therapeutic roles for IBAT inhibitors in metabolic liver disease: a case of NASH
    Dr Arun Sanyal
  5. IBAT inhibitors in clinical trials
    Dr Saul Karpen
  6. Panel discussion with interactive audience Q&A: what are the potential applications and possible pitfalls of IBAT inhibitors in clinical practice?
  7. Chair’s close
    Dr Saul Karpen

Audience

  • Primary Audience: Hepatologists/Pediatric Hepatologists, Gastroenterologists/Pediatric gastroenterologists
  • Secondary Audience: Transplant Surgeons

Learning objectives
After attending this symposium, learners will be able to:

  • Discuss the mechanism of action of ileal bile acid transporter (IBAT) inhibitors and their proposed effects on cholestatic liver disease and metabolic disease.
  • Describe the pathophysiological features of cholestatic liver diseases, as well as clinical outcomes associated with these conditions.
  • Describe the pathophysiological features of metabolic liver diseases, as well as clinical outcomes associated with these conditions.
  • Recall clinical trial data regarding the efficacy and safety of IBAT inhibitors in the treatment of cholestatic liver disease, including biliary atresia and progressive familial intrahepatic cholestasis (PFIC).

Presented for attendees of The Liver Meeting Digital Experience™. This event is sponsored by Liberum IME and supported by Albireo Pharmaceuticals. This is not an official event of the American Association for the Study of Liver Diseases.